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Abstract
Background—CFTR plays a key role in maintenance of lung fluid homeostasis. Cigarette 
smoke decreases CFTR expression in the lung but neither the mechanisms leading to CFTR loss, 
nor potential ways to prevent its loss have been identified to date.
Methods—The molecular mechanisms leading to down-regulation of CFTR by cigarette smoke 
were determined using pharmacologic inhibitors and silencing RNAs.
Results—Using human bronchial epithelial cells, here we show that cigarette smoke induces 
degradation of CFTR that is attenuated by the lysosomal inhibitors, but not proteasome inhibitors. 
Cigarette smoke can activate multiple signaling pathways in airway epithelial cells, including the 
MEK/Erk1/2 MAPK pathway regulating cell survival. Interestingly, pharmacological inhibition of 
the MEK/Erk1/2 MAPK pathway prevented the loss of plasma membrane CFTR upon cigarette 
smoke exposure. Similarly, decreased expression of Erk1/2 using silencing RNAs prevented the 
suppression of CFTR protein by cigarette smoke. Conversely, specific inhibitors of the JNK or 
p38 MAPK pathways had no effect on CFTR decrease after cigarette smoke exposure. In addition, 
inhibition of the MEK/Erk1/2 MAPK pathway prevented the reduction of the airway surface 
liquid observed upon cigarette smoke exposure of primary human airway epithelial cells. Finally, 
addition of the antioxidant NAC inhibited activation of Erk1/2 by cigarette smoke and precluded 
the cigarette smoke-induced decrease of CFTR.
Conclusions—These results show that the MEK/Erk1/2 MAPK pathway regulates plasma 
membrane CFTR in human airway cells.
General Significance—The MEK/Erk1/2 MAPK pathway should be considered as a target for 
strategies to maintain/restore CFTR expression in the lung of smokers.
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BACKGROUND
The cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel that 
plays a critical role in the lung by regulating airway fluid homeostasis allowing cilia to beat 
and clear pathogens [1]. Absence of functional CFTR leads to cystic fibrosis a genetic 
disease associated with impaired mucus clearance, and chronic infection and inflammation 
[2]. These past few years there has been a lot of interest in the negative regulation of CFTR 
by pollutants such as cigarette smoke, cadmium, and arsenic [3–6]. We and others have 
shown that CFTR expression is reduced in the lung of patients who developed chronic 
obstructive pulmonary disease (COPD) after years of cigarette smoking [7–9]. These 
findings suggest that suppression of CFTR could contribute to the development of chronic 
bronchitis seen in COPD which is characterized by mucus secretion, infection and 
inflammation similarly to what is observed in the lungs of patients with Cystic Fibrosis.
Suppression of CFTR can occur via degradation by two main pathways: the ubiquitin-
proteasome pathway and the lysosomal pathway [10–12]. Plasma membrane CFTR is 
rapidly endocytosed and undergoes rapid and efficient recycling back to the plasma 
membrane in human airway epithelial cells, with more than 75% of endocytosed wild-type 
CFTR recycling back to the plasma membrane [13–15]. The plasma membrane stability of 
CFTR depends on its biosynthetic processing and post-maturational trafficking, which 
involves endocytic uptake followed by recycling to the plasma membrane or degradation in 
the lysosomes [16, 17]. The E3 ubiquitin ligase c-Cbl has been shown to facilitate CFTR 
endocytosis and ubiquitination with subsequent lysosomal degradation [18]. The molecular 
mechanism by which cigarette smoke alters expression of the CFTR ion channel is still 
unknown. We have previously shown that using a heterologous expression system, cigarette 
smoke exposure causes rapid internalization of CFTR. During this internalization, CFTR 
does not co-localize with lysosomes [6] but is instead internalized into an aggresome-like 
pathway in a calcium-dependent manner [6, 19].
Cigarette smoke activates several mitogen-activated protein kinase (MAPK) pathways 
including the MEK/Erk1/2 MAPK pathway [20]. Activation of this latter MAPK pathway 
results in cell survival and proliferation [21]. It was recently shown that the MEK/Erk1/2 
MAPK pathway can regulate the expression of the epithelial sodium channel ENaC by 
regulating its interaction with the E3 ubiquitin ligase Nedd4-2 leading to lysosomal 
degradation of ENaC [22, 23]. Whether the MEK/Erk1/2 MAPK pathway also regulates the 
expression of plasma membrane CFTR is unknown.
Herein, we conducted this study to determine the underlying mechanisms by which cigarette 
smoke decreases CFTR abundance in human bronchial epithelial cells and determine the 
role of the MEK/Erk1/2 MAPK pathway in this process. We also evaluated whether the 
antioxidant N-acetyl-cysteine (NAC) could prevent the cigarette smoke-induced suppression 
of CFTR.
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Cell Culture and Reagents
The human bronchial epithelial cell line 16HBE14o-, an immortalized human bronchial 
epithelial cell line, was cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
containing L-glutamine, 10% FBS and penicillin (100 U/ml) and streptomycin (100 µg/ml). 
The tissue culture plates were coated using human fibronectin (1 mg/ml), collagen I bovine 
(3 mg/ml), and bovine serum albumin (1 mg/ml). All the cells used in the experiments were 
between passages 25 and 50, and were grown and maintained at 37 °C in a 5% CO2 
humidified incubator. Primary human bronchial epithelial cells (HBECs) were isolated from 
excess donor tissue obtained at the time of lung transplantation under a protocol approved 
by UNC Medical School IRB. Primary HBECs were cultured as previously described and 
studied when fully differentiated [6, 24]. Lactacystin, UO126, UO124, SB203580, and 
SP600125 were from Calbiochem (La Jolla, CA). PD98059 was purchased from Cell 
Signaling Technology. The proteasome inhibitor MG132, and the lysosomal inhibitors, 
leupeptin and chloroquine, were purchased from Sigma-Aldrich (St. Louis, MO).
Cell Transfection
16HBE14o- cells were transfected with Erk1 and Erk2 small interfering RNAs (siRNA), cbl 
siRNA (Ambion), or negative control #1 siRNA (Ambion) using Lipofectamine 2000 
reagent (Invitrogen) according to the manufacturer’s instructions. Forty eight hours after 
transfection, cells were treated with or without 10% cigarette smoke extract (CSE) prepared 
from Camel cigarettes (R.J. Reynolds). The cells were then lysed in PBS with 1% Triton 
X-100 containing a cocktail of protease inhibitors (Roche Diagnostics, IN) for protein 
analysis.
Cell Surface Biotinylation
The 16HBE14o- cells were rinsed with ice-cold phosphate-buffered saline (PBS) containing 
0.1mM CaCl2 and 1mM MgCl2 to eliminate the proteins present in the media. Cell surface 
proteins were labeled with 1 mg/ml EZ-Link NHS-SS Biotin (Pierce) for 30 min at 4 °C. 
Biotinylation was stopped by removing the biotin solution and incubating the cells with PBS 
containing 1% bovine serum albumin for 10 min at 4 °C to quench any residual NHS-SS 
biotin. At the end of the experiment, the cells were lysed with PBS-1% Triton X-100 and 
protease inhibitors (Roche). Biotinylated proteins were incubated with streptavidin beads 
overnight at 4 °C. After extensive washings, bound proteins were subjected to Western blot 
analysis. Biotinylated CFTR was detected using a C-CFTR monoclonal antibody (24-1; 
R&D Systems).
Immunoblotting
Cells were lysed in PBS containing 1% Triton X-100 and a cocktail of protease inhibitors 
(Roche). Western blotting was performed as previously described [4]. In brief, 20 µg of the 
protein were separated with SDS-PAGE in 4–15% polyacrylamide gel and then transferred 
to polyvinylidenedifluoride (PVDF) membranes (Bio-Rad, Hercules, CA). The membranes 
were blocked with 5% non-fat milk in PBS-Tween 20 and immunoblotted with primary 
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antibodies against CFTR antibody (24-1, R&D Systems), phosphor-Erk1/2 (Cell Signaling), 
Erk1/2 (Cell Signaling), or β-actin (Santa Cruz Biotechnology) followed by treatment with 
appropriate HRP-conjugated secondary antibody (Pierce, Rockford, IL, USA). The signals 
were detected with enhanced chemiluminescence (Super Signal West Pico; Thermo 
Scientific) followed by exposure to X-ray films. The protein bands on the X-ray film were 
scanned, and band density was measured using ImageJ software (NIH).
ASL height measurements
To measure ASL height, PBS (20 µl) containing 2 mg/ml rhodamine-dextran (10 kDa; 
Invitrogen, USA) ± 10 µM MEK inhibitor was added to cultures at the start of the 
experiment for 10 mins. To measure ASL secretion, excess fluid was aspirated with a 
Pasteur pipette to bring ASL height down to ~ 7 µm, as described by Tarran et al. [25]. 
Before CS exposure, 10 µM MEK inhibitor was added basolateraly. In all cases, five 
predetermined points (one central, four 2 mm from the edge of the culture) were XZ scanned 
using a confocal microscope (Leica SP5; glycerol 63× immersion lens) as described [26]. 
Cultures were returned to the incubator between time points. For all studies, PFC was added 
mucosally during imaging to prevent evaporation of the ASL.
Cigarette smoke extract (CSE) preparation and whole Cigarette Smoke (CS) exposure
CSE (100%) was prepared as previously described and used to treat 16HBE14o- cells [27]. 
Primary HBECs were exposed to whole cigarette smoke (CS) after being placed in a 
specially built smoke exposure chamber that exposes apical but not basolateral surfaces [6, 
28]. CS was then generated according to the International Organization of Standardization 
(ISO) standards (35 ml draw over 2 s) using a LC1 smoke engine (Borgwaldt, Richmond, 
Virginia, USA) and applied to the cultures at a rate of 1 puff every 30 s until the cigarette is 
smoked (~ 5 min; ~ 12 puffs). For ASL experiments cells are treated with CS for about 5 
min. This maneuver has previously been shown to drive removal of CFTR from the plasma 
membrane without inducing gross cellular toxicity [6, 28].
Confocal Microscopy
16HBE14o- cells were fixed in ice-cold 100% methanol for 20 min at −20°C. The slides 
were then incubated in 1% bovine serum albumin (BSA)/PBS for 10 min, followed by 
incubation at 37 °C for 1 hr with primary antibody against CFTR (24-1; R&D Systems) and 
the lysosomal marker LAMP-1 (Cell Signaling Technology). After several washings, the 
slides were incubated at 37 °C for 45 min with appropriate Alexa Fluor® 488- and Alexa 
Fluor® 594-conjugated secondary antibody. Coverslips were mounted onto slides with 
Vectashield mounting medium containing DAPI (Vector Laboratories) prior to being 
imaged on a Leica DMIRE2 inverted confocal microscope using a 63× objective lens.
Statistical Analysis
Data are expressed as mean ± standard error (SE) of at least three independent experiments. 
The results of the experiments were analyzed by unpaired t tests. In all cases, a p value of 
<0.05 was considered as statistically significant.
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Effect of lysosomal and proteasome inhibitors on cigarette smoke extract (CSE)-induced 
decrease of CFTR protein in human airway epithelial cells
Several studies have recently shown that CSE decreases the expression of CFTR in human 
airway epithelial cells [3, 6, 27]. Here we used the normal human bronchial epithelia cell 
line 16HBE14o- that endogenously expresses the ion channel CFTR. The main two 
pathways leading to CFTR degradation are the proteasomal and lysosomal pathways [5, 11, 
29]. In order to investigate whether the underlying pathway involves either lysosomes or the 
proteasome, 16HBE14o- cells were treated with CSE in presence of the lysosomal or 
proteasome inhibitors. As expected, CSE reduced the expression of CFTR (Figure 1). It has 
to be noted that only mature CFTR (Band C) is seen on the blots. This result is in agreement 
with previous report showing that CFTR biogenesis is very efficient (close to 100%) in cells 
endogenously expressing CFTR such as 16HBE14o- [30]. The lysosomal inhibitors 
chloroquine (Figure 1A) and leupeptin (Figure 1B) both significantly prevented the CSE-
induced decrease of CFTR, but they both had no effect on steady state level of CFTR. As 
previously described [6] the proteasomal inhibitor MG132 did not prevent CFTR diminution 
after CSE exposure (Figure 1A). However MG132 alone decreased CFTR expression. We 
therefore used another proteasomal inhibitor lactacystin (Figure 1C) which had no effect on 
steady-state levels of CFTR. Again, this inhibitor could not preclude the loss of CFTR 
induced by CSE exposure. Taken together our data show that cigarette smoke induces 
lysosomal degradation of CFTR.
Role of MAPK pathways in CSE-induced suppression of CFTR
Cigarette smoke contains over 3,000 chemicals including reactive oxygen species (ROS) 
that can act on various pathways in the cell. Accordingly, CSE can stimulate multiple 
signaling pathways including mitogen-activated protein kinase (MAPK) pathways. We 
therefore investigated whether the main classical MAPK pathways (i.e. p38, JNK, and 
MEK) contribute to the decrease in the expression of CFTR protein after CSE exposure. As 
shown in Figure 2A, inhibition of the MEK/Erk1/2 MAPK pathway using two specific 
inhibitors, UO126 and PD98059, prevented the loss of CFTR induced by CSE. These results 
were further confirmed using UO124, the inactive form of UO126 which has no inhibitory 
property on MEK, and had no protective effect on CFTR after exposure to cigarette smoke 
(Figure 2B). UO124 alone had no effect on the expression of CFTR (p > 0.05). Although 
UO126 alone has a trend to increase the expression of CFTR when compared with the 
control group, this increase failed to reach significance (p = 0.063, Supplemental Figure 1). 
Conversely, inhibition of the p38 or JNK MAPK pathways had no effect on the suppression 
of CFTR after exposure of human bronchial epithelial cells 16HBE14o- to CSE (Figure 2A).
To further confirm the role of Erk1/2 in down-regulation of CFTR by CSE, the expression 
of Erk1/2 was decreased using silencing RNAs targeting Erk1 and Erk2. As shown in Figure 
3, the expression of Erk1 and Erk2 was decreased by about 50%. No difference in the 
expression of CFTR was observed between the control and Erk siRNA groups in absence of 
CSE treatment. Addition of CSE reduced the expression of CFTR in the control group but 
reduced expression of Erk1/2 significantly prevented the loss of CFTR protein. To confirm 
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that Erk silencing was sufficient to impair downstream phosphorylation of Erk targets, 
phosphorylation of Elk was detected. As observed in Fig. S1, addition of CSE increased 
phosphorylation of Elk which was prevented in cells treated with Erk siRNAs.
Inhibition of the MEK/Erk1/2 MAPK pathway prevents the loss of CFTR from the plasma 
membrane of human airway epithelial cells after CSE exposure
CFTR has to be present at the plasma membrane of bronchial epithelial cells to exert its role 
as a chloride channel and regulate the airway surface hydration [1]. We therefore wanted to 
determine whether inhibition of the MEK/Erk1/2 MAPK pathway would have any 
protective effect on plasma membrane CFTR after exposure to CSE. The human bronchial 
epithelial cells 16HBE14o- were incubated simultaneously with CSE and the MEK/Erk1/2 
inhibitor UO126 and CFTR present at the plasma membrane was assessed using cell surface 
biotinylation. Not only inhibition of the MEK/Erk1/2 MAPK pathway prevented decrease of 
CFTR protein (Figure 4A), it also prevented the loss of CFTR from the plasma membrane of 
airway epithelial cells (Figure 4B).
Inhibition of the MEK MAPK pathway prevents cigarette smoke-induced decrease of 
airway surface liquid (ASL)
CFTR is present at the plasma membrane of bronchial epithelial cells and regulates 
hydration of the airway surface liquid layer [1]. As seen in cystic fibrosis, absence of 
functional CFTR results in impaired mucociliary clearance due to reduced ASL. We recently 
showed that cigarette smoke decreases expression of membrane CFTR in primary human 
bronchial epithelial cells resulting in impaired ASL [27]. As shown above (Figure 4B), 
inhibition of the MEK MAPK pathway prevented the decrease of plasma membrane CFTR. 
Accordingly, inhibition of the MEK pathway using the specific inhibitor UO126 prevented 
the reduction in the height of the ASL observed upon exposure to cigarette smoke (Figure 
4C).
Role of the E3 ligase c-Cbl on CFTR expression after exposure to cigarette smoke
Ubiquitination of CFTR can lead to proteasomal or lysosomal degradation. The E3 ubiquitin 
ligase c-Cbl has been shown to be linked to lysosomal degradation of CFTR in airway 
epithelial cells [18, 31]. To determine whether c-Cbl is involved in the CSE-induced 
degradation of CFTR, we used c-Cbl siRNA to decrease c-Cbl abundance. As shown in 
Figure 5, transfection of c-Cbl siRNA reduced c-Cbl expression by ~77%. The CFTR 
expression was comparable between the control and c-Cbl siRNA groups in absence of CSE 
treatment. Conversely, addition of CSE significantly decreased the expression of CFTR in 
the control group, whereas suppression of c-Cbl expression using siRNA partly prevented 
the CSE-induced down-regulation of CFTR. These data indicate that the E3 ligase c-Cbl 
contributes to suppression of CFTR upon cigarette smoke exposure.
Inhibition of the MEK/Erk1/2 pathway prevents lysosomal degradation of CFTR
Lysosome-associated membrane protein 1 (LAMP-1) is a marker of the lysosomes and was 
used to determine the intracellular localization of CFTR. As shown in Figure 6 and S2, using 
confocal microscopy the CFTR signal was reduced after exposure to CSE as expected. No 
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co-localization of CFTR with LAMP-1 was observed in 16HBE14o- cells in those 
conditions and could be due to CFTR degradation preventing its detection with the antibody 
used. However, inhibition of lysosmal degradation using chloroquine (CQ) allowed 
detection of CFTR in the lysosomes when the cells were exposed to CSE. The co-
localization of CFTR with LAMP-1 was reduced in presence of the MEK/Erk1/2 inhibitor 
UO126. These results suggest that CSE induces lysosomal degradation of CFTR in human 
bronchial epithelial cells via activation of the MEK/Erk1/2 MAPK pathway.
The antioxidant N-acetylcysteine (NAC) prevents the CSE-induced loss of CFTR
Cigarette smoke contains many chemical compounds as well as reactive oxygen species 
(ROS) that can trigger activation of signaling pathways such as MEK/Erk1/2 [20]. N-
acetylcysteine (NAC) is an antioxidant that can inhibit ROS directly via the redox potential 
of its thiol or indirectly by increasing intracellular glutathione levels. We therefore 
investigated whether NAC could prevent the loss of CFTR after exposure to CSE. Cells 
were treated with NAC and CSE simultaneously and CFTR expression was analyzed 24 
hours later. As observed in Figure 7A, addition of 10 mM NAC prevented the loss of CFTR 
due to CSE exposure. NAC alone had no effect on CFTR expression (Figure 7A). Since the 
data presented above show that CSE alters the expression of the CFTR protein via activation 
of the MEK/Erk1/2 MAPK pathway, we investigated whether NAC prevented the loss of 
CFTR after CSE exposure by blocking activation of Erk1/2 (phosphorylation). CSE induced 
activation of Erk1/2 as shown by detection of phosphorylated Erk1/2 (Figure 7B) which was 
inhibited in the presence of 10 mM NAC. A lower concentration of 2 mM NAC had little 
effect on CSE-induced decrease of CFTR or phosphorylation of Erk1/2 (Figures 7A and 
7C).
DISCUSSION
In this study we investigated the molecular mechanism by which cigarette smoke suppresses 
expression of CFTR in human bronchial epithelial cells. Our results revealed that cigarette 
smoke negatively regulates CFTR via activation of the MEK/Erk1/2 MAPK pathway. We 
found that cigarette smoke leads to internalization of the CFTR ion channel, and inhibition 
of the MEK/Erk1/2 MAPK pathway prevented the cigarette smoke-induced loss of CFTR as 
well as decreased of airway surface liquid (ASL). In addition we show that the antioxidant 
NAC prevented the loss of CFTR by inhibiting Erk1/2 phosphorylation.
Dr. Welsh’s laboratory was the first to report that cigarette smoke inhibits chloride ion 
transport across tracheal epithelium [32]. Several reports have shown that cigarette smoke 
inhibits the expression and function of the ion channels CFTR and ENaC [6, 8, 33, 34] and 
recently, a cigarette smoke-induced increase in intracellular calcium has been implicated in 
CFTR internalization[19]. However, key questions remain regarding the molecular pathway 
leading to CFTR deregulation. In this study, we used normal bronchial epithelial cell line 
16HBE14o- which endogenously expresses CFTR since many studies used cells derived 
from cancer or heterologous systems with cells overexpressing CFTR. Consistent with a 
previous study where Bafilomycin A1 prevented CFTR inhibition, here we show that the 
lysosomal inhibitors, chloroquine and leupeptin, prevented the loss of CFTR, whereas 
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inhibition of the proteasome had no effect. However, CFTR could not be detected in the 
lysosomes using immunohistochemistry in presence of CSE and could be due to CFTR 
degradation preventing its detection. Absence of co-localization of CFTR and LAMP-1 were 
previously reported [6] even though lysosomes have been shown to contribute to CFTR 
degradation [10]. Conversely, addition of the lysosmal inhibitor chloroquine, which prevents 
acidification of the lysosomes, allowed co-localization of CFTR with the lysosomal marker 
LAMP-1 (see Figure 6). Bafilomycin A1 inhibits smoke-induced calcium release and also 
prevents CFTR diminution [19]. Thus, sorting out effects caused by altered lysosomal 
calcium release versus inhibition of lysosomal degradation are hard to differentiate and 
additional studies will be required. Interestingly, the heavy metal arsenic has been shown to 
trigger lysosomal degradation of the CFTR ion channel in airway epithelial cells [18, 31]. 
Taken together, these results suggest that targeting the lysosomes would prevent CFTR 
degradation upon exposure to pollutants.
Lysosmal degradation of membrane proteins is generally associated with 
monoubiquitination. C-Cbl is an E3 ligase previously reported to facilitate the lysosomal 
degradation of CD5, gp130, as well as CFTR [18, 31, 35, 36]. However, decreasing the 
expression of c-Cbl using silencing RNA prevented the CSE-induced suppression of CFTR 
suggesting that c-Cbl contributes to regulation of CFTR in human bronchial epithelial cells.
The epithelial sodium channel ENaC which interacts with CFTR in bronchial epithelial cells 
[37, 38] is degraded by the lysosomes after activation of the MEK/Erk1/2 MAPK pathway 
by interacting with the E3 ligase Nedd4-2 [39–41]. Here we show that pharmacological 
inhibition of MEK using UO126 or PD98059, or genetic inhibition of Erk1/2 using siRNAs 
prevented the cigarette smoke-induced suppression of CFTR. Most importantly, inhibition 
of the MEK/Erk1/2 MAPK pathway prevented the loss of CFTR from the plasma membrane 
of the human bronchial epithelial cells 16HBE and most importantly prevented the cigarette 
smoke-induced decreased of ASL. This is an important finding since CFTR needs to be 
present at the apical membrane of airway epithelial cells to play its role as a chloride 
channel to maintain fluid homeostasis in the lung. Activation of the Erk1/2 pathway by the 
pollutant cadmium was reported to increase CFTR activity in kidney cells [42]. In this latter 
study, CFTR activity was measured 5 minutes after exposure to cadmium. It is therefore 
possible that activation of Erk1/2 has distinct effects depending of the type of cells studied 
(renal versus airway epithelial cells) and/or the time after MEK/Erk1/2 activation (short-
term versus long-term). Since both CFTR and ENaC are downregulated following activation 
of the MEK/Erk1/2 MAPK pathway, it might be an unrecognized pathway to regulate 
plasma membrane ion channels.
About 20% of smokers develop chronic obstructive pulmonary disease (COPD) but over 
90–95% of patients with COPD were smokers (http://www.goldcopd.com). Some reports 
indicate that as many as 50% of smokers develop COPD if an advanced age is reached [43]. 
Cigarette smoke contains over 3,000 chemicals as well as reactive oxygen species that can 
lead to activation of several signaling pathways including the MEK/Erk1/2 MAPK pathway 
[20]. For example our team has recently showed that cadmium, a toxic heavy metal present 
in cigarette smoke, induces secretion of the pro-inflammatory cytokine IL-8 via an Erk1/2-
dependent pathway when added to human bronchial epithelial cells [44]. Interestingly, 
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sustained activation of Erk1/2 has been found in mice and rats exposed to cigarette smoke 
[45, 46]. Most importantly, analysis of phospho-Erk1/2 revealed that patients with COPD 
(emphysema) have elevated Erk activation when compared to healthy control subjects [20, 
45]. Based on our results we predict that sustained activation of Erk in the lung will 
contribute to suppression of CFTR expression.
NAC has been used in patients with COPD with mixed success [47, 48]. Recently it was 
shown that higher doses might be required to obtain beneficial effects [49]. Several studies 
reported that long-term high dose of NAC treatment may reduce the risk of exacerbations 
and improve lung function (FEV1) [50, 51]. The doses used in our study are within the range 
of doses used in clinical practice (4–10 mM daily) [50]. We observed that 2 mM NAC had 
very little inhibitory effect on activation of Erk1/2 MAPK pathway, whereas 10 mM 
prevented activation of Erk1/2 and consequently loss of CFTR protein (see Figures 7A and 
C). It is important to note that the cells were not pre-treated with NAC so the protective 
effect of NAC is not due to increased levels of glutathione but rather by acting directly as an 
antioxidant. In addition, the inhibition of Erk1/2 activation was seen only after 5–10 minutes 
(see Figure 7). Interestingly, Varelogianni et al. reported that NAC increases chloride efflux 
via activation of the CFTR chloride channel in human bronchial epithelial cells expressing 
the CFTR mutant deltaF508 [52]. This latter mutation is the most common mutation leading 
to cystic fibrosis (CF). Since CF cells have higher Erk1/2 activation when compared to 
control non-CF cells [53] it is possible that NAC could inhibit the MEK/Erk1/2 pathway in 
CF cells resulting in rescue of deltaF508-CFTR. Accordingly, a recent study identified 
kinase inhibitors, including inhibitors of the Ras/Raf/MEK/Erk1/2 pathway as potent 
correctors of deltaF508-CFTR.
GENERAL SIGNIFICANCE
Due to the role of CFTR in the bronchial epithelium and its potential role in chronic 
bronchitis seen in COPD patients, our data suggest that NAC would benefit COPD patients 
with chronic bronchitis by inhibiting activation of the MEK/Erk1/2 pathway resulting in 
stabilization of plasma membrane CFTR.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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- The Erk pathway contributes to degradation of CFTR in cells exposed to 
CSE
- Inhibition of the Erk pathway prevents loss of membrane CFTR and 
impairment of ASL
- High doses of the NAC inhibits activation of Erk pathway
- High doses of NAC precludes cigarette smoke-induced decrease of CFTR
- We report that targeting Erk pathway improves stability of CFTR in 
bronchial cells
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Figure 1. Effect of the lysosomal inhibitors leupeptin and chloroquine and the proteasomal 
inhibitor lactacystin on the expression of CFTR after exposure to cigarette smoke extract
16HBE14o- cells were treated with 10% cigarette smoke extract (CSE) with or without the 
lysosomal inhibitor leupeptin (LP, 50 µg/ml) or chloroquine (CQ, 10 µM), or the proteasome 
inhibitor lactacystin (LC, 5 µM) for 48 hrs. CFTR protein was detected by immunoblotting 
as described in Methods. CTRL, Control. N=4. *, p < 0.05; **, p < 0.001; NS, not 
significant.
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Figure 2. Role of MAPK inhibitors on CFTR expression after cigarette smoke exposure
16HBE14o- cells were treated with 10% CSE with or without the MEK/Erk1/2 inhibitors 
UO126 (10 µM) or PD98059 (PD, 20 µM), the p38 inhibitor SB203580 (SB, 20 µM), the 
JNK inhibitor SP600125 (JNKi, 20 µM), or UO124 (10 µM) for 48 hrs. CFTR protein was 
detected by immunoblotting. CTRL, Control. N=4. *, p < 0.05; **, p < 0.001; NS, not 
significant.
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Figure 3. Decreased expression of Erk1 and 2 prevents the CSE-induced suppression of CFTR
16HBE14o- cells were incubated with Erk1 and 2 siRNAs or control siRNA. Forty eight 
hours later 16BE14o- cells were incubated with 10% CSE for 24 hrs. CFTR and Erk 1 and 2 
proteins were detected by immunoblotting. β-actin was detected to confirm equal loading 
between samples. CTRL, Control. N=4.*, p < 0.05; **, p < 0.001.
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Figure 4. Inhibition of the MEK/Erk1/2 MAPK pathway prevents loss of plasma membrane 
CFTR after cigarette smoke exposure
(A) and (B) 16HBE14o- cells were treated with 10% Camel cigarette smoke extract (CSE) 
with or without UO126 (10 µM) for 48 hrs. CFTR expression (total (A) or plasma 
membrane (B)) was detected as described in Methods. CTRL, Control. N=4. (C) Primary 
human bronchial epithelial cells were pretreated with 10 µM UO126 and then exposed to air 
or cigarette smoke (CS) as described in Methods section. ASL was measured at the indicated 
time. N=6 from two normal donors. *, p < 0.05; **, p < 0.001
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Figure 5. Effect of the E3 ligase c-Cbl on CFTR expression after exposure to CSE
16HBE14o- cells were transfected with c-Cbl or control siRNA for 48 hrs, followed by 
treatment with 10% Camel cigarette smoke extract (CSE) for 24 hrs. CFTR and c-Cbl were 
detected by immunoblotting. β-actin was detected to confirm equal loading between 
samples. CTRL, Control. N=4. *, p < 0.05; **, p < 0.001.
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Figure 6. Effect of CSE on intracellular localization of CFTR
Representative confocal microscopic images of CFTR (Alexa488, green color) and LAMP-1 
(Alexa594, red color)-stained cells. 16HBE14o- cells were treated with 10% CSE with or 
without the lysosomal inhibitor chloroquine (CQ, 20 µg/ml) and the MEK/Erk1/2 MAPK 
inhibitor UO126 (10 µM) for 24 hrs. Representative images showing the co-localization of 
CFTR and LAMP-1 are shown. CTRL: Control. Original magnification 630×.
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Figure 7. The antioxidant N-Acetylcysteine (NAC) prevents suppression of CFTR upon cigarette 
smoke exposure
(A) 16HBE14o- cells were treated with 10% CSE with or without 0.5, 2, or 10 mM NAC. 
CFTR protein was detected by immunoblotting. N=4. *, p < 0.05; **, p < 0.001. (B) 
16HBE14o- cells were treated with 10% CSE for the indicated times. PhosphoErk1/2 and 
total Erk1/2 were detected by immunoblotting. N=4. (C) 16HBE14o- cells were treated with 
10% CSE with or without NAC (2 or 10 mM) for the indicated time. Phospho-Erk1/2 was 
detected by immunoblotting. Blots are representative of at least three experiments.
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